https://orcid.org/0000-0002-5528-3197
Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Marissa Mock, Alex W. Jacobitz, Christopher James Langmead, Athena Sudom, Daniel Yoo, Sara C. Humphreys, Mai Alday, Larysa Alekseychyk, Nicolas Angell, Vivian Bi, Hannah Catterall, Chen-Chun Chen, Hui-Ting Chou, Kip P. Conner, Kevin D. Cook, Ana R. Correia, Andrew Dykstra, Sudipa Ghimire-Rijal, Kevin Graham, Peter Grandsard, Joon Huh, John O. Hui, Mani Jain, Victoria Jann, Lei Jia, Sheree Johnstone, Neelam Khanal, Carl Kolvenbach, Linda Narhi, Rupa Padaki, Emma M. Pelegri-O’Day, Wei Qi, Vladimir Razinkov, Austin J. Rice, Richard Smith, Christopher Spahr, Jennitte Stevens, Yax Sun, Veena A. Thomas, Sarah van Driesche, Robert Vernon, Victoria Wagner, Kenneth W. Walker, Yangjie Wei, Dwight Winters, Melissa Yang & Iain D. G. Campuzano. (2023) Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies. mAbs 15:1.
Read now
Read now
Young D. Kwon, Amarendra Pegu, Eun Sung Yang, Baoshan Zhang, Michael F. Bender, Mangaiarkarasi Asokan, Qingbo Liu, Krisha McKee, Bob C. Lin, Tracy Liu, Mark K. Louder, Reda Rawi, Mateo Reveiz, Andrew J. Schaub, Chen-Hsiang Shen, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola & Peter D. Kwong. (2023) Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain. mAbs 15:1.
Read now
Read now
Tushar Jain, Todd Boland & Maximiliano Vásquez. (2023) Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches. mAbs 15:1.
Read now
Read now
Catherine Y Liu, Cory L Ahonen, Michael E Brown, Ling Zhou, Martin Welin, Eric M Krauland, Robert Pejchal, Paul F Widboom & Michael B Battles. (2023) Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity. mAbs 15:1.
Read now
Read now
Carl Mieczkowski, Xuejin Zhang, Dana Lee, Khanh Nguyen, Wei Lv, Yanling Wang, Yue Zhang, Jackie Way & Jean-Michel Gries. (2023) Blueprint for antibody biologics developability. mAbs 15:1.
Read now
Read now
Monica L. Fernández-Quintero, Anne Ljungars, Franz Waibl, Victor Greiff, Jan Terje Andersen, Torleif T. Gjølberg, Timothy P. Jenkins, Bjørn Gunnar Voldborg, Lise Marie Grav, Sandeep Kumar, Guy Georges, Hubert Kettenberger, Klaus R. Liedl, Peter M. Tessier, John McCafferty & Andreas H. Laustsen. (2023) Assessing developability early in the discovery process for novel biologics. mAbs 15:1.
Read now
Read now
Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng-Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter & Andreas Baumann. (2022) Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper. mAbs 14:1.
Read now
Read now
Shihao Hu, Amita Datta-Mannan & David Z. D’Argenio. (2022) Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties. mAbs 14:1.
Read now
Read now
Shufang Liu, Ashwni Verma, Hubert Kettenberger, Wolfgang F. Richter & Dhaval K. Shah. (2021) Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. mAbs 13:1.
Read now
Read now
Roland E. Kontermann, Guy Ungerechts & Dirk M. Nettelbeck. (2021) Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. mAbs 13:1.
Read now
Read now
Nels Thorsteinson, John R. Gunn, Kenneth Kelly, Will Long & Paul Labute. (2021) Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics. mAbs 13:1.
Read now
Read now
Emily K. Makowski, Lina Wu, Priyanka Gupta & Peter M. Tessier. (2021) Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods. mAbs 13:1.
Read now
Read now
Articles from other publishers (19)
Valentin J. Hoerschinger, Franz Waibl, Nancy D. Pomarici, Johannes R. Loeffler, Charlotte M. Deane, Guy Georges, Hubert Kettenberger, Monica L. Fernández-Quintero & Klaus R. Liedl. (2023) PEP-Patch: Electrostatics in Protein–Protein Recognition, Specificity, and Antibody Developability. Journal of Chemical Information and Modeling 63:22, pages 6964-6971.
Crossref
Crossref
Shufang Liu & Dhaval K. Shah. (2023) Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies. The AAPS Journal 25:3.
Crossref
Crossref
Andreas Evers, Shipra Malhotra, Wolf-Guido Bolick, Ahmad Najafian, Maria Borisovska, Shira Warszawski, Yves Fomekong Nanfack, Daniel Kuhn, Friedrich Rippmann, Alejandro Crespo & Vanita Sood. 2023. Genotype Phenotype Coupling. Genotype Phenotype Coupling
383
398
.
Nels Thorsteinson, Stephen R. ComeauJrJr & Sandeep Kumar. 2023. Computer-Aided Antibody Design. Computer-Aided Antibody Design
219
235
.
Hannes Ausserwöger, Matthias M. Schneider, Therese W. Herling, Paolo Arosio, Gaetano Invernizzi, Tuomas P. J. Knowles & Nikolai Lorenzen. (2022) Non-specificity as the sticky problem in therapeutic antibody development. Nature Reviews Chemistry 6:12, pages 844-861.
Crossref
Crossref
Martin R. Edelmann. (2022) Radiolabelling small and biomolecules for tracking and monitoring. RSC Advances 12:50, pages 32383-32400.
Crossref
Crossref
James E. CroweJr.Jr.. (2022) Human Antibodies for Viral Infections. Annual Review of Immunology 40:1, pages 349-386.
Crossref
Crossref
Nicolas Frances, Marina Bacac, Katharine Bray-French, François Christen, Heather Hinton, Elisabeth Husar, Elizabeth Quackenbush, Martin Schäfer, Eginhard Schick, Arthur Van De Vyver & Wolfgang F. Richter. (2022) Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. Journal of Pharmaceutical Sciences 111:4, pages 1208-1218.
Crossref
Crossref
Deni Hardiansyah & Chee Meng Ng. (2022) Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague–Dawley Rats. Pharmaceutical Research 39:3, pages 481-496.
Crossref
Crossref
Jakob C. Stüber, Karin F. Rechberger, Saša M. Miladinović, Thomas Pöschinger, Tamara Zimmermann, Remi Villenave, Miro J. Eigenmann, Thomas E. Kraft, Dhaval K. Shah, Hubert Kettenberger & Wolfgang F. Richter. (2022) Impact of charge patches on tumor disposition and biodistribution of therapeutic antibodies. AAPS Open 8:1.
Crossref
Crossref
Daniela Bumbaca Yadav, Kapil Gadkar & Isabel Figueroa. 2022. Haschek and Rousseaux's Handbook of Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology
77
100
.
M. W. Giese, R. H. Woodman, G. T. Hermanson & P. D. Davis. 2021. Chemical Linkers in Antibody–Drug Conjugates (ADCs). Chemical Linkers in Antibody–Drug Conjugates (ADCs)
286
376
.
Martin Siegemund, Prajakta Oak, Eva-Maria Hansbauer, Andrea Allersdorfer, Karoline Utschick, Alexandra Winter, Christina Grasmüller, Gunther Galler, Jan-Peter Mayer, Benjamin Weiche, Josef Prassler, Roland E. Kontermann & Christine Rothe. (2021) Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains. Frontiers in Pharmacology 12.
Crossref
Crossref
Martin R. Edelmann & Simon Hauri. (2021) Functional in vitro assessment of modified antibodies: Impact of label on protein properties. PLOS ONE 16:9, pages e0257342.
Crossref
Crossref
Chang Liu, Yeon Su Kim, John Hok-Nin Lowe & Shan Chung. (2021) A cell-based FcRn-dependent recycling assay for predictive pharmacokinetic assessment of therapeutic antibodies. Bioanalysis 13:14, pages 1135-1144.
Crossref
Crossref
Maxime Lecerf, Alexia Kanyavuz, Sofia Rossini & Jordan D. Dimitrov. (2021) Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities. Communications Biology 4:1.
Crossref
Crossref
Manali S. Sawant, Craig N. Streu, Lina Wu & Peter M. Tessier. (2020) Toward Drug-Like Multispecific Antibodies by Design. International Journal of Molecular Sciences 21:20, pages 7496.
Crossref
Crossref
Yuki Noguchi, Kazuhisa Ozeki & Hidetaka Akita. (2020) Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells. Scientific Reports 10:1.
Crossref
Crossref
Genki Nakamura, Kazuhisa OzekiMiho NagayasuTakeru NambuTakayuki NemotoKen-ichi Hosoya. (2020) Predicting Method for the Human Plasma Concentration–Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates. Biological and Pharmaceutical Bulletin 43:5, pages 823-830.
Crossref
Crossref